

## Avanse Financial Services Limited

September 07, 2023

Facilities/Instruments	Amount (₹ crore)	Rating <sup>1</sup>	Rating Action
Long-term bank facilities	7,200.00	CARE AA-; Stable	Reaffirmed
Long-term instruments	25.00	CARE AA-; Stable	Reaffirmed
Long-term instruments	25.00	CARE AA-; Stable	Reaffirmed
Long-term instruments	25.00	CARE AA-; Stable	Reaffirmed
Market-linked debentures	100.00	CARE PP-MLD AA-; Stable	Reaffirmed
Market-linked debentures	100.00	CARE PP-MLD AA-; Stable	Reaffirmed
Market-linked debentures	300.00	CARE PP-MLD AA-; Stable	Reaffirmed
Market-linked debentures	100.00	CARE PP-MLD AA-; Stable	Reaffirmed
Market-linked debentures	400.00	CARE PP-MLD AA-; Stable	Reaffirmed
Non-convertible debentures	960.00	CARE AA-; Stable	Assigned
Non-convertible debentures	40.00 (Reduced from 55.00)	CARE AA-; Stable	Reaffirmed
Non-convertible debentures	350.00	CARE AA-; Stable	Reaffirmed
Non-convertible debentures	150.00 (Reduced from 400.00)	CARE AA-; Stable	Reaffirmed
Non-convertible debentures	500.00	CARE AA-; Stable	Reaffirmed
Non-convertible debentures	850.00 (Reduced from 1,000.00)	CARE AA-; Stable	Reaffirmed
Non-convertible debentures	500.00	CARE AA-; Stable	Reaffirmed
Non-convertible debentures <sup>^</sup>	-	-	Withdrawn
Non-convertible debentures <sup>^</sup>	-	-	Withdrawn
Non-convertible debentures <sup>^</sup>	-	-	Withdrawn
Non-convertible debentures <sup>^</sup>	-	-	Withdrawn
Commercial paper	300.00 (Enhanced from 150.00)	CARE A1+	Reaffirmed

Details of instruments/facilities in Annexure-1.

<sup>^</sup>The rating has been withdrawn at the request of the company and confirmation received from the debenture trustee that there is no amount outstanding.

### Rationale and key rating drivers

The ratings of the long-term bank facilities and various debt instruments of Avanse Financial Services Limited (AFSL) derives strength from its established market presence in the overseas education loan segment with continuous improvement in scale of operations, comfortable capitalisation levels, comfortable asset quality levels as reflected in relatively low gross non-performing assets (GNPA) primarily aided by its presence in the overseas education loan segment, which continues to have good asset quality. The rating factors in resultant improvement in profitability supported by improvement in scale of operations and other operating income related to lending business. Growth in operations were ably supported by periodical equity infusions with fresh equity infusions aggregating ₹990 crore during FY23 and additional infusion of ₹200 crore received during Q1FY24. This along with retention of profits resulted in improvement in tangible network from ₹983 crore as on March 31, 2022 to ₹2,378 crore as on June 30, 2023.

CARE Ratings Limited (CARE Ratings) notes that the discontinued segments of lending to Micro, Small & Medium Enterprises (MSME) and lending to financial institutions (LFI) are the major contributors to the bad loans, and the same has been running down. The discontinued segments accounted for 0.55% of the total assets under management (AUM) as on June 30, 2023. Excluding discontinued segments, Gross Stage 3 assets (GS3) stood at 0.40% as on March 31, 2023, as against overall GS3 of 0.56% as on March 31, 2023 (March 31, 2022: 1.24%). Nevertheless, the ratings continue to be constrained by relatively moderate but growing scale of operations as company mainly focuses on specialised lending, i.e., overseas education loans, inherent asset liability tenure mismatch arising due to relatively longer tenure of education loans and possibility of asset side risks considering the moderate seasoning of the EL segment loan book. It is to be noted that the asset quality of overseas education loans of domestic NBFCs remained relatively stable with low GS3/GNPA in the past many years. In respect of AFSL, GS3 stood in the range of 0.2% to 0.7% (EL segment) during the past five fiscals ended March 31, 2023, demonstrating resilience during COVID period also. While the assets side risks continue to exist due to uncertain global economic scenario, AFSL's asset quality track record in

<sup>1</sup>Complete definition of the ratings assigned are available at [www.careedge.in](http://www.careedge.in) and other CARE Ratings Ltd.'s publications

the overseas education loan segment and strong capitalisation level adds to comfort. The inherent asset liability tenure mismatch is partially mitigated due to significant prepayments in education loans as the behavioural tenure of these loans are shorter than contracted tenure. The ability of the company to further improve its borrowing profile and raise longer tenure borrowings will be key to improve its business profile.

### Rating sensitivities: Factors likely to lead to rating actions

#### Positive factors- Factors that could, individually or collectively, lead to positive rating action/upgrade

- Substantial increase in the scale as a result of steady growth, improvement in liability profile along with maintaining higher share of retail loan portfolio.
- Improvement in financial performance with ROTA of 3% or above along with stable asset quality on a sustained basis.

#### Negative factors- Factors that could, individually or collectively, lead to negative rating action/downgrade

- Any significant deterioration in asset quality with GNPA above 3% on sustained basis.
- Noticeable weakness in borrower's employability in key markets of operation.
- Asset Under Management (AUM) / Tangible Networth beyond 5.5 times.
- Significant increase in the proportion of wholesale (i.e., non-EL & digital) portfolio.

**Analytical approach:** Standalone

**Outlook:** Stable

CARE Ratings believes that the entity shall sustain its business and financial risk profile with credit cost under control over the medium term.

### Detailed description of the key rating drivers:

#### Key strengths

**Established market position in overseas education loan segment supported by continuous increase in scale of operations:** Company has an overall track record of 11 years of operations. Company is the second largest domestic private sector NBFC in overseas education loan segment with AUM of ₹9,881 crore as on June 30, 2023. Of this, EL stood at ₹7,303 crore (73.9% of AUM) as on June 30, 2023. In education loan segment, company extends loan to students mainly for overseas studies in around 50 countries with USA constituting 52.7% of EL loans followed by Canada (18.6%), UK (17.5%), India (5.6%) and others (5.6%) as on March 31, 2023.

Education Institution loan (EIL) and Social Infrastructure Loan (SIL) constitutes 18.0% of loan portfolio as on March 31, 2023 financing growth capital needs of educational institutes (schools) in India. Followed by Digital business constituting 7.6%, wherein company has active customer base of more than 1.50 lakh+ students catering to up skilling and test preparation segment. Discontinued business segment of lending to MSME and financial institution forms 0.55% of portfolio as on June 30, 2023 (March 31, 2023: 0.75%) which was a gradual run down.

**Comfortable capitalisation levels supported by demonstrated capital mobilisation including fresh equity capital infusion of ₹990 crore in FY23 and ₹200 crore in Q1FY24:** The CAR and Tier-1 CAR continues to remain comfortable at 24.85% and 24.34% respectively as on March 31, 2023 aided by equity infusion of ₹990 crore during FY23 (March 31, 2022: 22.96% and 21.61%) despite high AUM growth of 79% during FY23. The debt/equity ratio also improved to 3.25 times as on March 31, 2023 as against 3.63 times as on March 31, 2022. Warburg Pincus LLC and IFC have infused equity of ₹390 crore during September 2022 in the same proportion of existing shareholding by way of rights issue. Company on-boarded new investor Kedaara Capital Growth Fund III LLP ("Kedaara") in the month of January 2023 and raised ₹600 crore, by way of preferential allotment on a private placement basis, to Kedaara. Balance committed equity of ₹200 crore was received in June 2023. Tangible Networth base of the company has witnessed increase from ₹983 crore as on March 31, 2022 to ₹2,378 crore as on June 30, 2023 aided by equity infusions, providing the necessary capital for near-to-medium term growth. CARE Ratings expects AUM/networth to remain below 5.5 times.

**Improving profitability levels:** The ROTA has improved from 1.06% in FY21 to 1.40% in FY22 and further to 2.06% in FY23, primarily driven by combination of operating leverage on account of improvement in scale and growth in total income aided by growth in NII and other income including fees and commission income. Other income/average assets increased from 0.65% in FY22 to 1.39% in FY23. The other income also includes gain on derecognition of financial instrument amounting to ₹23.6 during

FY23 (FY22: nil), excluding the same other income/average assets increased to 1.08% in FY23. Net Interest Margin (NIM) has remained stable at 4.53% during FY23 as against 4.55% in FY22. The company's operational expenses/average total assets witnessed improvement from 3.08% in FY21 to 2.88% in FY22 and further to 2.52% during FY23 with benefits of increase in the scale of operations being derived. The credit costs stood marginally higher at 0.64% in FY23 as against 0.42% in FY22, however the same continues to remain relatively low. Return on net worth (RONW) has improved from 6.64% in FY22 to 10.16% in FY23, although this continues to be relatively moderate. Going forward, the company's ability to raise funds at competitive rates and exhibit improvement in the operational efficiency with reduction in operational expenses/ average total assets would be key to improve earnings from current levels.

**Comfortable asset quality excluding discontinued segments:** Gross Stage 3 (on AUM) assets witnessed improvement to 0.56% as on March 31, 2023 (March 31, 2022: 1.24%). The net Stage 3 assets also witnessed improvement from 0.52% as on March 31, 2022 to 0.17% as on March 31, 2023. The overall Provision coverage ratio on stage 3 assets stands at 69%. Barring NPAs from discontinued segment of Loans to Financial Institutions (LFI) and Loans to MSME segment, the Gross Stage 3 assets remains comfortable at 0.40% as on March 31, 2023 (0.54% as on March 31, 2022). Overall Gross Stage 3 assets and Net Stage 3 assets continues to remain comfortable at 0.63% and 0.19% respectively as on June 30, 2023. The asset quality of the education loans (EL) is largely driven by the earnings potential of the students. The asset quality risk is negated to a large extent with the company adopting student-led approach in its lending practices with estimated earning potential of students derived through combination of academic track record of the student, track record of university, employment opportunities of the course and the region. The company has governance structure in place with regular reviews at all levels. Detailed key risk indicators are tracked monthly and addressed. Continuous monitoring is carried out based on external environment, customer data and bureau trends and analytics driven early warning signals, propensity to bounce models, credit loss forecasting models, etc. It is to be noted that the asset quality of overseas education loans of domestic NBFCs remained relatively stable with low GS3/GNPA levels in the past many years (please refer to report on [Specialised Education NBFC's](#)). In respect of AFSL, GS3 stood in the range of 0.2% to 0.7% during the past five fiscals ended March 31, 2023, demonstrating resilience during COVID period also. While the assets side risks continue to exist due to uncertain global economic scenario, AFSL's asset quality track record in the overseas education loan segment, its established credit underwriting and strong capitalisation level adds comfort.

### Key weaknesses

**Moderate but growing scale of operations along with moderate seasoning of loan portfolio:** The company commenced business operations in January 2013. The company's AUM witnessed growth of 55.8% during FY22 and 79.4% during FY23 and stood at ₹8,646 crore as on March 31, 2023 (March 31, 2021: ₹3,103 crore). AUM grew by 13.9% during Q1FY24 and stood at ₹9,881 crore. Considering contracted tenure of majority of the loan book is around 10 years and high loan book growth achieved from FY22 with majority of loan book in education loan segment being under principal moratorium, the seasoning of the loan portfolio is moderate. However, the behavioural tenure of such loans are much lesser ranging from 5 to 7 years, benefitting the company, As stated earlier, factors such as established credit underwriting process and capitalisation levels provides comfort to an extent.

**Product and geographical concentration risk:** AFSL is primarily present into education loans exposing it to sector concentration risk as any fall in the demand for educational loan may impact the disbursements and profitability of the company. Also, educational loans have seasonal demand based upon the admission procedures in various institutions. AFSL has discontinued the MSME and LFI loan segments after change in the promoters in 2019. Thereafter, the company has been gradually diversifying into the digital segment (financing of up skilling and test preparation segment), which constitutes around 7.6% of the AUM as on June 30, 2023. Geographically, 52% of the loan portfolio in education loan segment is concentrated in the US followed by Canada (18.6%), UK (17.5%), India (5.6%), and rest constituting 5.6% in education loan book as on March 31, 2023.

**Inherent asset liability tenure mismatch arising due to longer tenure of education loans:** The company has improved diversification in its liability profile over the years. Loans from the banks form majority of the borrowings constituting 55.4% of overall borrowings as on June 30, 2023, followed by non-convertible debentures (NCDs) (39.7%), loans from financial institutions (FIs) (2.5%), ECB (1.3%). The company has an established lender base of 32 lenders as on March 31, 2023 and the share of borrowings from NBFCs has been on a declining trend. Incremental cost of borrowings raised during FY23 stood at 9.03%. The cost of borrowings had been relatively higher compared to some of the NBFCs having similar credit profile as majority of on-lending is towards non-PSL. The Company had been able to maintain NIM in FY23 at the same level of FY22. CARE expects the company to further reduce its cost of borrowings primarily supported by improved business and credit profile. Though liability profile has improved over the years, inherent asset liability tenure mismatch continues due to relatively longer tenure of loans extended (EL and EIL). Same is partially offset due to higher amount of prepayments in education loans. It is to be noted that in respect of education loans, the company extends loans for contracted tenure of around 10 years. However, the behavioural

tenure of such loans are much lesser ranging from 5 to 7 years, benefitting the company. As per ALM statement submitted as on March 31, 2023, there is no negative cumulative mismatch in upto one year period with cumulative surplus of ₹1,433 crore.

**Liquidity:** Adequate

The company generally maintains liquid balances to cover around 1.5 months of net outflows including disbursements. The free cash & bank balances and liquid investments stood at ₹1,072 crore as on March 31, 2023. The company also has undrawn sanction limits of ₹682 crore as on March 31, 2023. As a prudent measure, the company maintains cash and bank balance of minimum of 1.5-2 months of net cash outflows including disbursements.

**Assumptions/Covenants:** Not Applicable

**Environment, social, and governance (ESG) risks:** Not Available.

**Applicable criteria**

[Policy on Default Recognition](#)

[Financial Ratios – Financial Sector](#)

[Criteria on Assigning 'Outlook' or 'Rating Watch' to Credit Ratings](#)

[Policy on Withdrawal of Ratings](#)

[CARE Ratings' criteria for rating of Short-Term Instruments](#)

[Rating Methodology - Non-Banking Finance Companies](#)

[Criteria for rating of Market Linked Notes](#)

**About the company and industry**

**Industry classification**

Macro Economic Indicator	Sector	Industry	Basic Industry
Financial Services	Financial Services	Finance	Non Banking Financial Company (NBFC)

AFSL was formed in August 1992 and was known as Abhivruddhi Holdings Pvt. Ltd. (AHPL). Dewan Housing Finance Corporation Ltd. (DHFL) and other promoter group entities bought a 100% stake in AHPL in July 2012 and commenced education loan business from January 2013. International Finance Corporation (IFC) acquired a 20% stake in company for ₹12.75 crore in July 2013. On February 7, 2014, the name of the company was changed from Avanse Financial Services Private Limited to 'Avanse Financial Services Limited'. In March 2019, DHFL and WGC Group entered into a definitive agreement to sell 80% of its stake in AFSL to Olive Vine Investment Ltd, an affiliate of the Warburg Pincus Group. The deal was completed on July 30, 2019. AFSL is engaged in the business of providing education loan for the purpose of higher studies, both in India and abroad, and for professional/executive courses to working professional and to Education Institutions and schools for their working capital and growth capital requirements. Warburg Pincus and IFC have collectively infused ₹300 crores as growth capital in Avanse during FY20 and additional ₹390 crore was infused during September 2022. Company on-boarded new investor Kedaara Capital Growth Fund III LLP ("Kedaara") during January 2023 and raised ₹600 crore and ₹200 Cr was infused during Q1FY24, by way of preferential allotment on a private placement basis, to Kedaara. Post latest round of infusion the shareholding of Warburg stands at 66.97%, followed by IFC at 16.74% and Kedaara at 15.92% as on June 30, 2023. The company now has 12 branches across 8 cities in India. The total AUM stood at around ₹9,881 crore as on June 30, 2023.

Brief Financials (₹ crore)	March 31, 2022 (A)	March 31, 2023 (A)	June 30, 2023 (Prov)
Total operating income	508.54	990.23	342.60
PAT	63.21	157.73	62.23
Total Assets	5,500.09	9898.73	NA
Net NPA (%)	0.53	0.17	0.19
ROTA (%)	1.40	2.06	NA

A: Audited; NA: Not available. Note: The above results are the latest financial results available.

**Status of non-cooperation with previous CRA:** Not applicable

**Any other information:** Not applicable

**Rating history for the last three years:** Please refer Annexure-2

**Covenants of the rated instruments/facilities:** Detailed explanation of the covenants of the rated instruments/facilities is given in Annexure-3

**Complexity level of the various instruments rated:** Annexure-4

**Lender details:** Annexure-5

### Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance	Coupon Rate (%)	Maturity Date	Size of the Issue (₹ crore)	Rating Assigned along with Rating Outlook
Commercial Paper- Commercial Paper (Standalone)	INE087P14713	-	-	-	50.00	CARE A1+
Commercial Paper- Commercial Paper (Standalone)	Proposed	-	-	-	250.00	CARE A1+
Fund-based - LT-Cash Credit		-	-	-	147.00	CARE AA-; Stable
Fund-based - LT-Cash Credit	Proposed	-	-	-	43.00	CARE AA-; Stable
Fund-based - LT-Term Loan	-	-	-	March 2029	4713.94	CARE AA-; Stable
Fund-based - LT-Term Loan	Proposed	-	-	-	2296.06	CARE AA-; Stable
Non-convertible debentures	INE087P07022	31-Jul-15	10.10%	31-Jul-25	25	CARE AA-; Stable
Non-convertible debentures	INE087P07030	07-Aug-15	10.05%	08-Aug-22	5*	Withdrawn
Non-convertible debentures	INE087P07048	07-Aug-15	10.10%	07-Aug-25	15	CARE AA-; Stable
Non-convertible debentures	INE087P07063	26-Feb-16	9.65%	26-Feb-23	10*	Withdrawn
Non-convertible debentures	INE087P07113	12-Dec-19	11.40%	09-Dec-22	195*	Withdrawn
Non-convertible debentures	INE087P07121	18-Dec-19	11.40%	16-Dec-22	105*	Withdrawn
Non-convertible debentures	INE087P07139	24-Jun-20	9.50%	23-Jun-23	50*	Withdrawn
Non-convertible debentures	INE087P07147	07-Jul-20	9.50%	21-Apr-23	50*	Withdrawn
Non-convertible debentures	INE087P07162	27-Jul-21	8.40%	27-Jul-23	100*	Withdrawn
Non-convertible debentures	INE087P07170	30-Jul-21	8.40%	30-Jul-23	100*	Withdrawn
Non-convertible debentures	INE087P07188	26-Aug-21	8.40%	26-Aug-23	35	CARE AA-; Stable
Non-convertible debentures	INE087P07196	29-Sep-21	8.40%	29-Sep-23	250*	Withdrawn
Non-convertible debentures	INE087P07204	24-Mar-22	10.25%	24-Mar-25	150	CARE AA-; Stable
Non-convertible debentures	INE087P07212	19-Apr-22	8.04%	29-Sep-23	95*	Withdrawn
Non-convertible debentures	INE087P07220	21-Jul-22	9.55%	21-Dec-23	375	CARE AA-; Stable
Non-convertible debentures	INE087P07253	07-Sep-22	9.30%	07-May-24	200	CARE AA-; Stable
Non-convertible debentures	INE087P07261	07-Sep-22	9.30%	07-May-24	1	CARE AA-; Stable
Non-convertible debentures	INE087P07295	12-Jan-23	9.25%	12-Jan-26	250	CARE AA-; Stable
Non-convertible debentures	INE087P07303	01-Feb-23	9.25%	01-Feb-26	100	CARE AA-; Stable
Non-convertible debentures	INE087P07311	29-Mar-23	9.65%	29-Jun-26	75	CARE AA-; Stable
Non-convertible debentures	INE087P07329	30-May-23	9.50%	29-Jun-26	200	CARE AA-; Stable
Non-convertible debentures	INE087P07337	30-May-23	9.50%	29-May-26	500	CARE AA-; Stable
Non-convertible debentures	INE087P07345	21-Jul-23	9.40%	08-Jul-26	55	CARE AA-; Stable
Non-convertible debentures	INE087P07352	28-Jul-23	9.40%	28-Jul-28	25	CARE AA-; Stable
Non-convertible debentures	INE087P07345	28-Jul-23	9.40%	28-Jul-28	100	CARE AA-; Stable
Non-convertible debentures	INE087P07360	07-Aug-23	9.40%	08-Sep-26	100	CARE AA-; Stable
Non-convertible debentures	Proposed	-	-	-	184	CARE AA-; Stable
Non-convertible debentures	Proposed	-	-	-	960	CARE AA-; Stable
Debentures-Market-linked debentures	INE087P07238	02-Aug-22	Linked to	25-Jun-24	200	CARE PP MLD AA-; Stable



			6.54% Gsec 2032			
Debentures-Market-linked debentures	INE087P07246	26-Aug-22	Linked to 6.54% Gsec 2032	03-Oct-24	400	CARE PP MLD AA-; Stable
Debentures-Market-linked	INE087P07279	23-Sep-22	Linked to 6.54% Gsec 2032	31-Jan-25	150	CARE PP MLD AA-; Stable
Debentures-Market-linked debentures	INE087P07287	04-Nov-22	Linked to 6.54% Gsec 2032	04-Apr-25	250	CARE PP MLD AA-; Stable
Debt-Subordinate debt	INE087P08020	30-Jun-17	9.50%	30-Jun-27	25.00	CARE AA-; Stable
Debt-Subordinate debt	INE087P08038	27-Dec-17	9.35%	27-Dec-27	25.00	CARE AA-; Stable
Debt-Subordinate debt	INE087P08012	16-Mar-16	10.50%	16-Mar-24	25.00	CARE AA-; Stable

\*Company has redeemed these instruments

### Annexure-2: Rating history for the last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2023- 2024	Date(s) and Rating(s) assigned in 2022- 2023	Date(s) and Rating(s) assigned in 2021- 2022	Date(s) and Rating(s) assigned in 2020- 2021
1	Fund-based - LT- Term Loan	LT	7010.00	CARE AA-; Stable	1)CARE AA-; Stable (17-May- 23)	1)CARE A+; Positive (01-Nov- 22)  2)CARE A+; Positive (23-Sep- 22)  3)CARE A+; Positive (23-Aug- 22)  4)CARE A+; Positive (01-Aug- 22)  5)CARE A+; Positive (02-Jun- 22)	1)CARE A+; Stable (21-Sep- 21)	1)CARE A+; Stable (29-Sep- 20)

2	Debentures-Non Convertible Debentures	LT	-	-	1)CARE AA-; Stable (17-May-23)	1)CARE A+; Positive (01-Nov-22) 2)CARE A+; Positive (23-Sep-22) 3)CARE A+; Positive (23-Aug-22) 4)CARE A+; Positive (01-Aug-22) 5)CARE A+; Positive (02-Jun-22)	1)CARE A+; Stable (21-Sep-21)	1)CARE A+; Stable (29-Sep-20)
3	Fund-based - LT-Cash Credit	LT	190.00	CARE AA-; Stable	1)CARE AA-; Stable (17-May-23)	1)CARE A+; Positive (01-Nov-22) 2)CARE A+; Positive (23-Sep-22) 3)CARE A+; Positive (23-Aug-22) 4)CARE A+; Positive (01-Aug-22) 5)CARE A+; Positive	1)CARE A+; Stable (21-Sep-21)	1)CARE A+; Stable (29-Sep-20)

						(02-Jun-22)		
4	Term Loan-Long Term	-	-	-	-	1)CARE A+; Positive (02-Jun-22)	1)CARE A+; Stable (21-Sep-21)	1)CARE A+; Stable (29-Sep-20)
5	Debentures-Non Convertible Debentures	LT	40.00	CARE AA-; Stable	1)CARE AA-; Stable (17-May-23)	1)CARE A+; Positive (01-Nov-22) 2)CARE A+; Positive (23-Sep-22) 3)CARE A+; Positive (23-Aug-22) 4)CARE A+; Positive (01-Aug-22) 5)CARE A+; Positive (02-Jun-22)	1)CARE A+; Stable (21-Sep-21)	1)CARE A+; Stable (29-Sep-20)
6	Debt-Subordinate Debt	LT	25.00	CARE AA-; Stable	1)CARE AA-; Stable (17-May-23)	1)CARE A+; Positive (01-Nov-22) 2)CARE A+; Positive (23-Sep-22) 3)CARE A+; Positive (23-Aug-22)	1)CARE A+; Stable (21-Sep-21)	1)CARE A; Stable (29-Sep-20)



						4)CARE A+; Positive (01-Aug-22) 5)CARE A+; Positive (02-Jun-22)		
7	Fund-based - LT-Term Loan	-	-	-	-	1)CARE A+; Positive (02-Jun-22)	1)CARE A+; Stable (21-Sep-21)	1)CARE A+; Stable (29-Sep-20)
8	Fund-based - LT-Term Loan	-	-	-	-	1)CARE A+; Positive (02-Jun-22)	1)CARE A+; Stable (21-Sep-21)	1)CARE A+; Stable (29-Sep-20)
9	Fund-based - LT-Term Loan	-	-	-	-	1)CARE A+; Positive (02-Jun-22)	1)CARE A+; Stable (21-Sep-21)	1)CARE A+; Stable (29-Sep-20)
10	Fund-based - LT-Term Loan	-	-	-	-	1)CARE A+; Positive (02-Jun-22)	1)CARE A+; Stable (21-Sep-21)	1)CARE A+; Stable (29-Sep-20)
11	Debentures-Non Convertible Debentures	LT	-	-	1)CARE AA-; Stable (17-May-23)	1)CARE A+; Positive (01-Nov-22) 2)CARE A+; Positive (23-Sep-22) 3)CARE A+; Positive (23-Aug-22) 4)CARE A+; Positive (01-Aug-22)	1)CARE A+; Stable (21-Sep-21)	1)CARE A+; Stable (29-Sep-20)

						5)CARE A+; Positive (02-Jun-22)		
12	Debentures-Non Convertible Debentures	LT	-	-	1)CARE AA-; Stable (17-May-23)	1)CARE A+; Positive (01-Nov-22) 2)CARE A+; Positive (23-Sep-22) 3)CARE A+; Positive (23-Aug-22) 4)CARE A+; Positive (01-Aug-22) 5)CARE A+; Positive (02-Jun-22)	1)CARE A+; Stable (21-Sep-21)	1)CARE A+; Stable (29-Sep-20)
13	Fund-based - LT-Term Loan	-	-	-	-	1)CARE A+; Positive (02-Jun-22)	1)CARE A+; Stable (21-Sep-21)	1)CARE A+; Stable (29-Sep-20)
14	Debt-Subordinate Debt	LT	25.00	CARE AA-; Stable	1)CARE AA-; Stable (17-May-23)	1)CARE A+; Positive (01-Nov-22) 2)CARE A+; Positive (23-Sep-22) 3)CARE A+; Positive (23-Aug-22)	1)CARE A+; Stable (21-Sep-21)	1)CARE A; Stable (29-Sep-20)

						4)CARE A+; Positive (01-Aug-22)		
						5)CARE A+; Positive (02-Jun-22)		
15	Debt-Subordinate Debt	LT	25.00	CARE AA-; Stable	1)CARE AA-; Stable (17-May-23)	1)CARE A+; Positive (01-Nov-22) 2)CARE A+; Positive (23-Sep-22) 3)CARE A+; Positive (23-Aug-22) 4)CARE A+; Positive (01-Aug-22) 5)CARE A+; Positive (02-Jun-22)	1)CARE A+; Stable (21-Sep-21)	1)CARE A; Stable (29-Sep-20)
16	Debentures-Non Convertible Debentures	LT	-	-	1)CARE AA-; Stable (17-May-23)	1)CARE A+; Positive (01-Nov-22) 2)CARE A+; Positive (23-Sep-22) 3)CARE A+; Positive	1)CARE A+; Stable (21-Sep-21)	1)CARE A+; Stable (29-Sep-20)

						(23-Aug-22) 4)CARE A+; Positive (01-Aug-22) 5)CARE A+; Positive (02-Jun-22)		
17	Debentures-Non Convertible Debentures	LT	350.00	CARE AA-; Stable	1)CARE AA-; Stable (17-May-23)	1)CARE A+; Positive (01-Nov-22) 2)CARE A+; Positive (23-Sep-22) 3)CARE A+; Positive (23-Aug-22) 4)CARE A+; Positive (01-Aug-22) 5)CARE A+; Positive (02-Jun-22)	1)CARE A+; Stable (21-Sep-21)	1)CARE A+; Stable (29-Sep-20)
18	Commercial Paper-Commercial Paper (Standalone)	ST	300.00	CARE A1+	1)CARE A1+ (17-May-23)	1)CARE A1+ (01-Nov-22) 2)CARE A1+ (23-Sep-22) 3)CARE A1+	1)CARE A1+ (21-Sep-21) 2)CARE A1+ (01-Jun-21)	-

						(23-Aug-22) 4)CARE A1+ (01-Aug-22) 5)CARE A1+ (02-Jun-22)		
19	Debentures-Non Convertible Debentures	LT	150.00	CARE AA-; Stable	1)CARE AA-; Stable (17-May-23)	1)CARE A+; Positive (01-Nov-22) 2)CARE A+; Positive (23-Sep-22) 3)CARE A+; Positive (23-Aug-22) 4)CARE A+; Positive (01-Aug-22) 5)CARE A+; Positive (02-Jun-22)	1)CARE A+; Stable (21-Sep-21) 2)CARE A+; Stable (23-Aug-21)	-
20	Debentures-Non Convertible Debentures	LT	500.00	CARE AA-; Stable	1)CARE AA-; Stable (17-May-23)	1)CARE A+; Positive (01-Nov-22) 2)CARE A+; Positive (23-Sep-22) 3)CARE A+; Positive	-	-

						(23-Aug-22) 4)CARE A+; Positive (01-Aug-22) 5)CARE A+; Positive (02-Jun-22)		
21	Debentures-Market Linked Debentures	LT	100.00	CARE PP-MLD AA-; Stable	1)CARE PP-MLD AA-; Stable (17-May-23)	1)CARE PP-MLD A+; Positive (01-Nov-22) 2)CARE PP-MLD A+; Positive (23-Sep-22) 3)CARE PP-MLD A+; Positive (23-Aug-22) 4)CARE PP-MLD A+; Positive (01-Aug-22)	-	-
22	Debentures-Market Linked Debentures	LT	100.00	CARE PP-MLD AA-; Stable	1)CARE PP-MLD AA-; Stable (17-May-23)	1)CARE PP-MLD A+; Positive (01-Nov-22) 2)CARE PP-MLD A+; Positive (23-Sep-22)	-	-

						3)CARE PP-MLD A+; Positive (23-Aug-22)		
						4)CARE PP-MLD A+; Positive (01-Aug-22)		
23	Debentures-Market Linked Debentures	LT	300.00	CARE PP-MLD AA-; Stable	1)CARE PP-MLD AA-; Stable (17-May-23)	1)CARE PP-MLD A+; Positive (01-Nov-22) 2)CARE PP-MLD A+; Positive (23-Sep-22) 3)CARE PP-MLD A+; Positive (23-Aug-22)	-	-
24	Debentures-Market Linked Debentures	LT	100.00	CARE PP-MLD AA-; Stable	1)CARE PP-MLD AA-; Stable (17-May-23)	1)CARE PP-MLD A+; Positive (01-Nov-22) 2)CARE PP-MLD A+; Positive (23-Sep-22) 3)CARE PP-MLD A+; Positive (23-Aug-22)	-	-
25	Debentures-Market Linked Debentures	LT	400.00	CARE PP-MLD	1)CARE PP-MLD	1)CARE PP-MLD	-	-



				AA-; Stable	AA-; Stable (17-May- 23)	A+; Positive (01-Nov- 22)		
26	Debentures-Non Convertible Debentures	LT	850.00	CARE AA-; Stable	1)CARE AA-; Stable (17-May- 23)	2)CARE PP-MLD A+; Positive (23-Sep- 22)	-	-
27	Debentures-Non Convertible Debentures	LT	500.00	CARE AA-; Stable	1)CARE AA-; Stable (17-May- 23)	-	-	-
28	Debentures-Non Convertible Debentures	LT	960.00	CARE AA-; Stable				

\*Long term/Short term.

### Annexure-3: Detailed explanation of the covenants of the rated instruments/facilities

Not applicable

### Annexure-4: Complexity level of the various instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Commercial Paper-Commercial Paper (Standalone)	Simple
2	Debentures-Market Linked Debentures	Complex
3	Debentures-Non Convertible Debentures	Simple
4	Debt-Subordinate Debt	Complex
5	Fund-based - LT-Cash Credit	Simple
6	Fund-based - LT-Term Loan	Simple

### Annexure-5: Lender details

To view the lender wise details of bank facilities please [click here](#)

**Note on the complexity levels of the rated instruments:** CARE Ratings has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for any clarifications.

## Contact Us

<p><b>Media Contact</b></p> <p>Mradul Mishra Director <b>CARE Ratings Limited</b> Phone: +91-22-6754 3596 E-mail: <a href="mailto:mradul.mishra@careedge.in">mradul.mishra@careedge.in</a></p> <p><b>Relationship Contact</b></p> <p>Saikat Roy Senior Director <b>CARE Ratings Limited</b> Phone: 022 67543404 /136 E-mail: <a href="mailto:Saikat.Roy@careedge.in">Saikat.Roy@careedge.in</a></p>	<p><b>Analytical Contacts</b></p> <p>Sanjay Agarwal Senior Director <b>CARE Ratings Limited</b> Phone: 022- 6754 3500 / 582 E-mail: <a href="mailto:sanjay.agarwal@careedge.in">sanjay.agarwal@careedge.in</a></p> <p>Sudhakar P Director <b>CARE Ratings Limited</b> Phone: +91-44-2850 1003 E-mail: <a href="mailto:p.sudhakar@careedge.in">p.sudhakar@careedge.in</a></p> <p>Nikhil Hardikar Associate Director <b>CARE Ratings Limited</b> Phone: +91-22-6754 3410 E-mail: : <a href="mailto:Nikhil.Hardikar@careedge.in">Nikhil.Hardikar@careedge.in</a></p>
---	---

### About us:

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

### Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings. The ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

**For the detailed Rationale Report and subscription information,  
please visit [www.careedge.in](http://www.careedge.in)**